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a  b  s  t  r  a  c  t
We  attempted  to evaluate  a novel  puriﬁcation  method  of immunoglobulins  (IgGs)  by using  a mutant  type
of protein  A. Although  this  mutant  protein  A binds  to IgGs  at 5 ◦C,  the  IgGs  are  released  at  40 ◦C;  hence,
it was  designated  as  thermo-responsive  protein  A (TRPA).  We  aimed  to  purify  IgG1 from  the  culture
supernatant  of CHO cells  producing  AE6F4  human  monoclonal  IgG1.  AE6F4  IgG1 was puriﬁed  using  onlyeywords:
rotein A
hermo-responsive protein A
uriﬁcation of IgG
a  TRPA-ﬁlled  column  and  by modifying  the  temperature,  without  any  exposure  to acidic  conditions.
Furthermore,  the puriﬁed  AE6F4  IgG1  maintained  the  inherent  binding  afﬁnity  to  antigen,  while  this
property  was lost  in  AE6F4  IgG1 puriﬁed  using  a conventional  protein  A (CPA)  column  possibly  because
of  product  aggregation  and  fragmentation.  These  data suggest  that  IgG  is  sensitive to  acid  treatment;
however,  it can  be  highly  puriﬁed  with  retention  of  high  afﬁnity  by  using  a TRPA  column.  Further,  this
e use
 2013puriﬁcation  method  can  b
©
. Introduction
Antibodies are biologically active agents that regulate the
mmune system. Recently, the availability of antibodies for use
n drugs and diagnosis, and as a puriﬁcation tool for antigens
as greatly increased [1]. Immunoglobulins (Igs) can be puriﬁed
rom the blood of immunized animal, ascites of mice injected with
ybridomas, and culture supernatant of cells producing antibodies.
owever, these ﬂuids contain various impurities as well as the tar-
et Igs. Therefore, although time-consuming and troublesome, the
uriﬁcation of Igs from these ﬂuids is very important.
For IgG puriﬁcation, protein A-coupled afﬁnity chromatography
s widely used because protein A can speciﬁcally bind to the Fc
egion of IgG with high afﬁnity. However, during the puriﬁcation
rocess, the IgGs are loaded onto protein A column under neutral
ondition (around pH 7) and are then eluted under acidic conditions
pH 3–4). Thus, it is very difﬁcult to purify acid-sensitive IgGs, as
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the acidic conditions may  result in the denaturation and aggrega-
tion of IgGs and reduced puriﬁcation efﬁciency. In particular, when
purifying human monoclonal IgGs that are used as antibody drugs,
prevention of aggregation and inactivation of IgGs are the most
important issues [2–4].
To overcome these difﬁculties, we propose the use of a mutant
protein A (thermo-responsive protein A [TRPA]) [5–8]. TRPA can
be obtained as previously described [5]. Brieﬂy, mutations were
introduced into the IgG-binding domain of Protein A to decrease the
hydrophobicity of the side chains buried inside the domain. Such
mutations were designed to modulate the equilibrium between the
denatured state and native state so that the domain has the native
structure at low temperature, e.g., below 10 ◦C, while it denatures
at elevated, yet biologically acceptable temperatures, e.g., approx-
imately 40 ◦C. In the present study, IgG was  bound to TRPA at 5 ◦C,
and bound IgG was released at 40 ◦C. We  then evaluated the efﬁ-
ciency of mutant protein A in the puriﬁcation of native structured
IgG and the effects on its function.
2. Experimental methods
2.1. Materials and reagents
Open access under CC BY-NC-ND license.TRPA resin is made up of mutant protein A-coated porous
beads made of cross-linked polyvinyl alcohol (average particle
size: 60 m;  Nomadic Bio Science, Okayama, Japan). MabSelect (GE
D license.
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Culture supernatant of CHO cells
( AE6F4 IgG1 antibody )
↓ ↓
TRPA CPA
↓ ↓ ↓ ↓
Sample 1
Low pH
( pH 3.5, 1 h )
Sample 3
Low pH
( pH 3.5, 1 h )
↓ ↓
Sample 2 Sample 4
Fig. 1. Puriﬁcation process of human AE6F4 IgG1. Culture supernatant of CHO cells
producing human AE6F4 IgG1 was harvested and membrane ﬁltered using BioOp-
timal MF-SL. The supernatant was  applied to the TRPA and CPA columns, eluted,
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Pnd  designated as Samples 1 and 2, respectively. Furthermore, AE6F4 human IgG1
uriﬁed using TRPA and CPA was placed in acidic conditions for 1 h, neutralized to
H  5.0, and designated as Samples 3 and 4, respectively.
ealthcare Japan, Tokyo, Japan), a protein A-coated porous agarose
ead (average particle size: 85 m)  was used as the conventional
rotein A (CPA) resin. Human polyclonal antibody (IgG1, Benesis,
saka), human IgG1 (Sigma, St. Louis, MO), human IgG2 (Merck Mil-
ipore, Billerica, MA), human IgG4 (Abcam, Cambridge, MA), mouse
gG1 (Sigma), mouse IgG2 (Sigma), goat IgG1 (Sigma), chicken IgY
Wako Pure Chemical, Osaka, Japan), and rabbit IgG1 (Sigma) were
sed as control IgGs. AE6F4 cells were used as the human IgG1 pro-
ucer cell line [9]. BioOptimal MF-SL (Asahi Kasei Medical, Tokyo,
apan) was used to ﬁne-ﬁlter the culture medium. Cytokeratin 8
as purchased from Progen (Heidelberg, Germany).
.2. Puriﬁcation of IgG using protein A resin
The Tricorn 5/100 column (GE Healthcare) was ﬁlled using a 50%
lurry of TRPA or CPA, which was connected to an AKTAFPLC (GE
ealthcare). The temperature of the column ﬁlled with TRPA was
ontrolled by a temperature-regulated water bath. When purify-
ng IgG using the column ﬁlled with TRPA resin (TRPA column), we
pplied the ﬁltered culture supernatant containing AE6F4 IgG1 to
he TRPA column at a ﬂow rate of 0.4 mL/min at 2 ◦C. The TRPA col-
mn  was washed with 10 mL  of buffer 1 (20 mM phosphate buffer,
50 mM NaCl, pH 8.0), then kept in a water bath at 40 ◦C for 10 min.
ollowing this, AE6F4 IgG1 was eluted using buffer 1. The eluted
gG was designated as Sample 1 (Fig. 1, Table 1).
When purifying IgG using the column ﬁlled with CPA resin (CPA
olumn), we applied the ﬁltered culture supernatant containing
E6F4 IgG1 to the CPA column at room temperature at a ﬂow rate
f 0.4 mL/min. The CPA column was washed with 10 mL  of buffer
. Bound AE6F4 IgG1 was eluted using acidic buffer (50 mM citrate
uffer, pH 3.0, 300 mM NaCl), and neutralized to pH 5.0 with 5%
olume of 1 M Tris–HCl buffer, pH 8.0. The eluate was at the low
H condition prior to neutralization of the protein approximately
able 1
uriﬁcation process using TRPA and CPA.
Sample 1 Sample 2 
Protein A type TRPA TRPA 
Elution buffer 20 mM phosphate + 150 mM
NaCl (pH 8.0)
20 mM
phosphate + 150 m
(pH 8.0)
Elution temperature 40 ◦C 40 ◦C 
Neutralization buffer – – 
pH  after neutralization – – 
Low  pH buffer – Acetic acid 
Low  pH incubation – pH 3.5, 1 h 
Neutralization buffer – 1 M Tris–HCl (pH
pH  after neutralizaiton – pH 5.0 . A 1305 (2013) 149– 153
6 min. The eluted antibody was designated as Sample 3 (Fig. 1,
Table 1).
2.3. Low-pH treatment
The pH of the TRPA eluate was  adjusted to 3.5 by adding acetic
acid, incubated for 1 h at room temperature, and neutralized to pH
5.0 by adding 1 M Tris–HCl (pH 8.0); this sample was designated as
Sample 2. The pH of the CPA eluate was  adjusted to 3.5 by adding
acetic acid, incubated for 1 h at room temperature, and neutral-
ized to pH 5.0 by adding 1 M Tris–HCl (pH 8.0); this sample was
designated as Sample 4 (Fig. 1, Table 1).
2.4. Isolation of monomer AE6F4 IgG1 by size-exclusion column
chromatography
Eluates treated as above (Samples 1–4) containing 5–10 mg of
AE6F4 IgG1 were applied to size-exclusion column chromatogra-
phy (SEC; HiLoad 16/60 Superdex 200 prep grade, GE Healthcare)
using sodium phosphate buffer (50 mM phosphate, 150 mM NaCl,
pH 7.2) at a ﬂow rate of 1.0 mL/min. The elution proﬁle was  mon-
itored at an absorbance of 280 nm,  and the main peak fraction
consisting of the monomer AE6F4 IgG1 was  collected.
2.5. Analysis of afﬁnity between AE6F4 IgG1 and cytokeratin 8
using a surface plasmon resonance (SPR) biosensor
Real-time analysis of the interaction between AE6F4 IgG1 and
cytokeratin 8 was studied using SPR measurements (Biacore J, GE
Healthcare). Cytokeratin 8 was  coupled onto a sensor chip CM5
(GE Healthcare) using an Amino Coupling kit (GE Healthcare). For
binding experiments, the Biacore J was  operated at 25 ◦C; ﬁltered
(0.22 m)  and degassed HBS-EP running buffer (GE Healthcare)
was used for all assays. The contact time of analyte and ligand was
limited to 120 s. For SPR biosensor analysis, 70 L of solution con-
taining AE6F4 IgG1 was injected at a ﬂow rate of 30 L/min. Each
experiment was performed at least in triplicate. The KD value was
calculated using BIAEvaluation in the Biacore J program.
3. Results and discussion
3.1. The effect of temperature on the binding of IgG to TRPA
Human polyclonal IgG1 was dissolved at a concentration of
5 mg/mL  in sodium phosphate buffer (neutral buffer, 20 mM phos-
phate, 150 mM NaCl, pH 8.0). This IgG1 solution was applied to the
temperature-controlled TRPA column from 2 ◦C to 40 ◦C. The col-
umn  was  washed using neutral buffer, and the bound IgG1 was
eluted by raising the column temperature to 40 ◦C.
The temperature-dependent IgG1 binding capacity to the TRPA
column is shown in Fig. 2. The concentration of IgG1 in the
Sample 3 Sample 4
CPA CPA
M NaCl
50 mM citrate + 300 mM
NaCl (pH 3.0)
50 mM citrate + 300 mM
NaCl (pH 3.0)
25 ◦C 25 ◦C
1 M Tris–HCl (pH 8.0) 1 M Tris–HCl (pH 8.0)
pH 5.0 pH 5.0
– Acetic acid
– pH 3.5, 1 h
 8.0) 1 M Tris–HCl (pH 8.0)
– pH 5.0
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Fig. 2. Effect of column temperature on the binding of IgG1 to TRPA resin. Human
polyclonal IgG1 (5 mg/mL in 20 mM phosphate and 150 mM NaCl, pH 8.0) was
applied to the temperature-controlled TRPA column at 2–40 ◦C. After the column
was  washed using the buffer, bound IgG was eluted by raising the temperature to
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Table 2
Static binding capacity of IgG to protein A.
Species Subclass Static binding capacity of IgG (mg/mL
chromatography adsorbent)
Conventional protein A
resin (25 ◦C)
Thermo-responsive
protein A resin (10 ◦C)
Mouse IgG1 3.6 0.2
IgG2 4.7 0.6
Goat IgG1 12.4 3.4
Chicken IgY 0.4 0.7
Rabbit IgG1 13.4 10.4
Human IgG1 15.1 10.7
F
s0 ◦C. The concentration of IgG1 in the eluate was  determined by the absorbance at
80 nm and the molar extinction coefﬁcient of IgG.
luate was determined by the absorbance at 280 nm and the
olar extinction coefﬁcient of IgG (1.35 L/[mol cm]). The maximum
inding capacity of human IgG1 was estimated to be 46 mg/mL
esin at 2 ◦C. As the temperature increased, the IgG1 binding capac-
ty decreased. At 40 ◦C, the TRPA resin was unable to bind to IgG1.
hese results indicate that TRPA, a mutant type of protein A, binds
trongly to human IgG1 at low temperature, but does not bind at
emperatures higher than 40 ◦C under neutral buffering conditions.
n addition, this temperature-dependent binding to the TRPA col-
mn  was observed for human IgG2 and human IgG4, suggesting
hat this technology can be widely used for other subclasses of IgGs
Fig. S1).
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.chroma.
013.07.015.
Furthermore, after binding at 2 ◦C and elution at 40 ◦C, the TRPA
olumn can be cleaned by treatment with 8 M urea. Human IgG1
as then loaded onto this restored TRPA column at 2 ◦C, and cap-
ured IgG1 was eluted at 40 ◦C. The amount of eluted IgG1 was
lmost the same as that of applied IgG1. This cleaning procedure
as performed for 10 cycles, and the adbsorbent cleanability was
onﬁrmed. These results indicate that the TRPA column is resistant
o the cleanup procedure by using 8 M urea and tolerant to repeated
se for industrial production processes.
ig. 3. Elution proﬁle of AE6F4 IgG1. Culture supernatant was applied to the TRPA and CPA
ection.  The elution proﬁles by using the (A) TRPA and (B) CPA columns are shown.IgG2 15.4 5.7
IgG4 10.9 10.8
3.2. Binding afﬁnity of TRPA to various IgGs
We assessed the static binding capacity of TRPA with various IgG
subtypes derived from various animals. All IgGs were dissolved in
neutral buffer at a concentration of 0.5 mg/mL. TRPA (0.01 mL) was
added to the IgG solution (1.0 mL)  and incubated at 10 ◦C for 1 h.
After this, the concentration of IgG in the supernatant was  deter-
mined by the absorbance at 280 nm,  and the static binding capacity
of TRPA was  calculated.
CPA (0.01 mL)  was  added to the antibody solution (1.0 mL)  and
incubated at room temperature for 1 h. The pH was then adjusted
to 3.0 by adding acetic acid, and the supernatant was recovered.
The static binding capacity of CPA was  calculated as mentioned
previously. The static binding capacities of TRPA and CPA to vari-
ous IgGs are shown in Table 2. These data demonstrated that TRPA
was unable to bind IgGs derived from mice, suggesting that the
mutations introduced into protein A affect the binding of TRPA to
mouse-derived IgG. However, other IgGs bound similarly to TRPA
and CPA.
3.3. Puriﬁcation of human IgG1
3.3.1. Puriﬁcation of human IgG1 using TRPA and CPA
Culture supernatant containing AE6F4 IgG1 was  ﬁltered using
the precise membrane (BioOptimal MF-SL, Asahi Kasei Medical).
The supernatant was applied to TRPA and CPA columns, and the
captured AE6F4 IgG1 was  eluted as described above. Elution pro-
ﬁles when using TRPA and CPA columns are shown in Fig. 3A and B,
respectively. We  applied 16.1 mg/mL  (TRPA) and 27.1 mg/mL (CPA)
of IgG1 to the respective columns, which corresponded to about
80% of the dynamic binding capacity for IgG1 at 10% breakthrough
(20 mg/mL  IgG1 for TRPA and 35 mg/mL  for CPA). The recovery
rate of AE6F4 IgG1 was 88% when using the TRPA column and was
30% when using the CPA column. These results indicate that elu-
tion at pH 3.0 is not an optimal recovery condition for AE6F4 IgG1,
 columns, and the captured AE6F4 IgG1 was eluted as described in the Experimental
152 I. Koguma et al. / J. Chromatogr. A 1305 (2013) 149– 153
Fig. 4. Size-exclusion column chromatography (SEC) analysis of AE6F4 IgG1. Elution proﬁles of SEC for AE6F4 IgG1 puriﬁed by the (A) TRPA and (B) CPA column before (solid
l ture.
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Table 3
Binding afﬁnity of IgG1 puriﬁed using TRPA and CPA.
ka (M−1 s−1) kd (s−1) KD (M) Relative
binding afﬁnity
Sample 1 1.06E+04 2.77E−03 2.61E−07 100
Sample 2 5.18E+03 1.19E−01 2.30E−05 1ines)  and after (dotted lines) exposure to acidic conditions for 1 h at room tempera
uggesting the need for optimizing the elution conditions for each
gG when using the CPA column.
.3.2. Molecular species of AE6F4 IgG1 analyzed by size-exclusion
hromatography
We next analyzed the molecular species of AE6F4 IgG1 puriﬁed
y using the TRPA and CPA columns by SEC. AE6F4 IgG1 puri-
ed by the TRPA column showed almost a single monomer peak
Sample 1, Fig. 4A) and a small shoulder peak. On the other hand,
E6F4 IgG1 puriﬁed by the CPA column contained several molecu-
ar species, possibly corresponding to aggregated IgG1 with a high
olecular weight and degraded IgG1 with a low molecular weight
s well as monomer (Sample 3, Fig. 4B). The formation of these
olecules could be attributed to the acidic elution buffer that was
sed.
Next, AE6F4 IgG1 puriﬁed using TRPA and CPA was placed in
n acidic condition for 1 h, and then applied to SEC (Samples 2 and
, respectively). Results showed that these IgG1s showed different
lution proﬁles after the low pH treatment. AE6F4 IgG1 puriﬁed
sing the TRPA column and subsequent low pH treatment was
luted as a single peak, devoid of the shoulder peak adjacent to the
ain peak (Fig. 4A, dotted line). Retention time of the main peak
emained unchanged upon the low pH treatment. The disappear-
nce of the shoulder peak might be caused by the dissociation of
ggregated antibody by the low pH treatment. On the other hand,
E6F4 IgG1 puriﬁed by using the CPA column showed a complex
lution proﬁle after the low pH treatment (Fig. 4B, dotted line). The
mount of high and low molecular weight species increased and the
etention time of the main peak increased upon low pH treatment.
hese results suggest that AE6F4 IgG1 puriﬁed using the CPA col-
mn is susceptible to aggregation and degradation possibly because
t went through the acid elution at pH 3.0. The structure of AE6F4
gG1 could be more fragile against acid treatment. Aggregation of
E6F4 IgG1 formed possibly by inappropriate interactions would
issociate by transient exposure to pH 3.5 (Fig. 4A), but transient
xposure to pH 3.0 would denature AE6F4 IgG1 and increase the
ggregation (Fig. S2). Taken together, these data suggest that when
urifying IgGs with an acid-sensitive structure, puriﬁcation using
he TRPA column is more suitable than puriﬁcation using the CPA
olumn; sensitive and unstable IgGs can be puriﬁed using the TRPA
olumn.
Supplementary data associated with this article can be
ound, in the online version, at http://dx.doi.org/10.1016/j.chroma.
013.07.015..3.3. Binding afﬁnity of AE6F4 IgG1 to cytokeratin 8
The afﬁnities of AE6F4 IgG1 puriﬁed by using the TRPA and CPA
olumns (Samples 1 and 3) and those treated at low pH (Samples 2Sample 3 1.59E+04 1.74E−02 1.09E−06 24
Sample 4 5.07E+03 5.09E−02 1.00E−05 3
and 4) with antigen (cytokeratin 8) were determined using BiacoreJ
(Table 3). First, results show that the KD value of AE6F4 IgG1 puri-
ﬁed using the TRPA column (Sample 1) for cytokeratin 8 was lower
than that of AE6F4 IgG1 puriﬁed using the CPA column (Sample
3), indicating that the binding afﬁnity of AE6F4 IgG1 puriﬁed using
the TRPA column was  more than 4-fold higher than that of AE6F4
IgG1 puriﬁed using the CPA column. These results suggest that
AE6F4 IgG1 puriﬁed using the TRPA column (Sample 1) maintains
the native structure and binding afﬁnity against antigen possibly
because AE6F4 IgG1 was  eluted from the TRPA column under mild
conditions (neutral buffer, pH 8.0) without any exposure to acidic
conditions. On the other hand, AE6F4 IgG1 puriﬁed using the CPA
column (Sample 3) is likely partially denatured, which could reduce
the binding afﬁnity for antigen possibly due to exposure to acidic
conditions (pH 3.0).
Furthermore, both binding afﬁnities of AE6F4 IgG1 puriﬁed
using TRPA and CPA against antigen were greatly decreased upon
acid treatment (Samples 2 and 4). These results suggest that AE6F4
IgG1 is sensitive to acid treatment, and the structure of AE6F4 IgG1
is easily denatured upon acid treatment, resulting in decreased
binding afﬁnity to antigen. Thus, the TRPA column is best suited
for the puriﬁcation of acid-sensitive IgGs, and it may  be applica-
ble for the industrial-scale puriﬁcation of IgGs that could denature
upon acid elution using the CPA column.
4. Conclusion
IgG1 was puriﬁed using the TRPA column by only modulating
the temperature, with no exposure to acidic conditions. When using
the TRPA column, IgG1 was puriﬁed mainly as a monomer. On the
other hand, IgG1 puriﬁed using the CPA column contained various
molecular species such as aggregated and degraded IgG1. Further-
more, IgG1 puriﬁed using TRPA maintained the inherent binding
afﬁnity to antigen, while this ability was  decreased in IgG1 puri-
ﬁed by CPA. These results suggest that this IgG1 is sensitive to
acid treatment, but can be highly puriﬁed with retention of high-
afﬁnity binding using the TRPA column, even for industrial scale
puriﬁcation of antibody drugs.
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